WO2000047193A3 - Inhibition of angiogenesis with epigallocatechin-3-gallate - Google Patents

Inhibition of angiogenesis with epigallocatechin-3-gallate Download PDF

Info

Publication number
WO2000047193A3
WO2000047193A3 PCT/IB2000/000193 IB0000193W WO0047193A3 WO 2000047193 A3 WO2000047193 A3 WO 2000047193A3 IB 0000193 W IB0000193 W IB 0000193W WO 0047193 A3 WO0047193 A3 WO 0047193A3
Authority
WO
WIPO (PCT)
Prior art keywords
angiogenesis
epigallocatechin
gallate
egcg
retinopathy
Prior art date
Application number
PCT/IB2000/000193
Other languages
French (fr)
Other versions
WO2000047193A2 (en
Inventor
Yihai Cao
Original Assignee
Karolinska Innovations Ab
Yihai Cao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab, Yihai Cao filed Critical Karolinska Innovations Ab
Priority to AU25673/00A priority Critical patent/AU2567300A/en
Publication of WO2000047193A2 publication Critical patent/WO2000047193A2/en
Publication of WO2000047193A3 publication Critical patent/WO2000047193A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Epigallocatechin-3-gallate (EGCG) inhibits angiogenesis and is useful in treatment and prevention of angiogenesis-dependent and -related diseases, including rheumatoid arthritis, psoriasis, ocular angiogenic diseases, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal angiogenesis, graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularisation, telangiectasia, hemophiliac joints, angiofibroma, wound granulation, cat scratch disease (Rochele minalia quintosa) and ulcers (Helicobacter pyloriinfection). EGCG may be provided by means of green tea.
PCT/IB2000/000193 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate WO2000047193A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU25673/00A AU2567300A (en) 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900473A SE9900473D0 (en) 1999-02-12 1999-02-12 Inhibitor of endothelial cell proliferation
SE9900473-1 1999-02-12

Publications (2)

Publication Number Publication Date
WO2000047193A2 WO2000047193A2 (en) 2000-08-17
WO2000047193A3 true WO2000047193A3 (en) 2001-12-06

Family

ID=20414446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000193 WO2000047193A2 (en) 1999-02-12 2000-02-14 Inhibition of angiogenesis with epigallocatechin-3-gallate

Country Status (3)

Country Link
AU (1) AU2567300A (en)
SE (1) SE9900473D0 (en)
WO (1) WO2000047193A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5089400A (en) * 1999-06-07 2000-12-28 University Of Sheffield, The Arthritis treatment
US6248341B1 (en) * 2000-01-14 2001-06-19 Color Access, Inc. Method of treating topical angiogenesis-related disorders
WO2002064178A1 (en) * 2001-02-15 2002-08-22 William Ransom & Son Plc Use of green tea extract for wound healing
GB0103742D0 (en) * 2001-02-15 2001-04-04 William Ransom & Son Plc Wound healing
RU2004123099A (en) 2001-12-28 2005-04-20 Рисерч Дивелопмент Фаундейшн (US) POLYPHENOL INHIBITION OF NUCLEOSIDE DIPHOSPHATKINASE B ACTIVITY AND METASTASIS OF CANCER
FR2842102B1 (en) * 2002-07-10 2005-10-28 Cep USE OF A TEA EXTRACT TO CONTROL THE RELEASE OF IL8, PRO-INFLAMMATORY CYTOKINE AND ITS INCORPORATION INTO COSMETIC AND / OR DERMATOLOGICAL PREPARATIONS
PT102931B (en) * 2003-03-28 2005-08-31 Univ Do Porto USE OF BLOCKERS OF THE LONG TERM INHIBITION OF THE ACTIVITIES OF ATPASE NA + K + E / OR OF THE NA + / H + EXCHANGE, IN THE PREPARATION OF A MEDICATION INTENDED FOR THE THERAPYTESTINAL
WO2005000330A1 (en) 2003-05-28 2005-01-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Angiogenic agents from plant extracts, gallic acid, and derivatives
KR100601080B1 (en) 2004-08-26 2006-07-19 가톨릭대학교 산학협력단 Rheumatoid arthritis treating agent having --epigallocatechin gallate as active ingredient
US20070249545A1 (en) * 2004-08-27 2007-10-25 Rodriguez-Lopez Jose N Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
EP1704862A1 (en) * 2005-03-24 2006-09-27 Rottapharm S.p.A. 2,5-bis(tetrahydroxybutyl)pyrazines for the treatment of osteoarthritis and rheumatoid arthritis
DE102005029845B4 (en) * 2005-06-27 2017-03-23 Orgentec Diagnostika Gmbh Method for the diagnosis of rheumatic diseases
EP2044951A1 (en) 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
US20090226547A1 (en) * 2008-03-05 2009-09-10 Gilbard Jeffrey P Dietary Supplement For Eye Health
TW201412325A (en) * 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
CN108272794A (en) * 2018-01-17 2018-07-13 苏州大学 The application of Epigallo-catechin gallate (EGCG)
CN114948935B (en) * 2022-03-28 2024-05-17 厦门大学 Gallic acid derivative nano-drug, preparation method and application

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913909A (en) * 1985-04-16 1990-04-03 Mitsui Norin Co., Ltd. Complex of tea-leaf extract and active aluminum hydroxide
JPH02264720A (en) * 1989-04-04 1990-10-29 Nikken Food Kk Oxidation-resistant stress substance
JPH05139972A (en) * 1991-11-25 1993-06-08 Taiyo Kagaku Co Ltd Composition for preventing gastritis and gastric or duodenal ulcer
JPH08217674A (en) * 1995-02-16 1996-08-27 Noda Sangyo Kagaku Kenkyusho Inhibitor of histidine decarboxylase
WO1996028178A1 (en) * 1995-03-14 1996-09-19 Indena S.P.A. Polyphenol fractions of tea, the use thereof and formulations containing them
EP0742012A2 (en) * 1995-05-10 1996-11-13 Kureha Chemical Industry Co., Ltd. Pharmaceutical composition containing substance inhibiting HSP47 production
JPH09227374A (en) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd Composition for inhibiting production of stress protein
DE19627344A1 (en) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutic composition containing epicatechin and/or theaflavin
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
JP2000226329A (en) * 1998-12-04 2000-08-15 Meiji Milk Prod Co Ltd Mmp inhibitor

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913909A (en) * 1985-04-16 1990-04-03 Mitsui Norin Co., Ltd. Complex of tea-leaf extract and active aluminum hydroxide
JPH02264720A (en) * 1989-04-04 1990-10-29 Nikken Food Kk Oxidation-resistant stress substance
JPH05139972A (en) * 1991-11-25 1993-06-08 Taiyo Kagaku Co Ltd Composition for preventing gastritis and gastric or duodenal ulcer
JPH08217674A (en) * 1995-02-16 1996-08-27 Noda Sangyo Kagaku Kenkyusho Inhibitor of histidine decarboxylase
WO1996028178A1 (en) * 1995-03-14 1996-09-19 Indena S.P.A. Polyphenol fractions of tea, the use thereof and formulations containing them
EP0742012A2 (en) * 1995-05-10 1996-11-13 Kureha Chemical Industry Co., Ltd. Pharmaceutical composition containing substance inhibiting HSP47 production
JPH09227374A (en) * 1996-02-28 1997-09-02 Taiyo Kagaku Co Ltd Composition for inhibiting production of stress protein
DE19627344A1 (en) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutic composition containing epicatechin and/or theaflavin
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
JP2000226329A (en) * 1998-12-04 2000-08-15 Meiji Milk Prod Co Ltd Mmp inhibitor

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
CAO Y ET AL: "ANGIOGENESIS INHIBITED BY DRINKING TEA", NATURE,MACMILLAN JOURNALS LTD. LONDON,GB, vol. 398, 1 April 1999 (1999-04-01), pages 381, XP000953295, ISSN: 0028-0836 *
CARLIN B I ET AL: "Green tea polyphenols inhibit growth of prostate cancer xenograft CWR22: Implications for prostate cancer chemoprevention.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 281, XP000961188, ISSN: 0197-016X *
CHEMICAL ABSTRACTS, vol. 133, Columbus, Ohio, US; abstract no. 172213, AKIZAWA, TOSHIFUMI ET AL: "Catechin derivatives as matrix metalloprotease (MMP) inhibitors for treatment of MMP-related diseases" XP002154308 *
DATABASE WPI Section Ch Week 199049, Derwent World Patents Index; Class B04, AN 1990-365881, XP002154311 *
DATABASE WPI Section Ch Week 199327, Derwent World Patents Index; Class B02, AN 1993-216659, XP002154309 *
DATABASE WPI Section Ch Week 199644, Derwent World Patents Index; Class B02, AN 1996-439471, XP002154310 *
DATABASE WPI Section Ch Week 199745, Derwent World Patents Index; Class B02, AN 1997-486360, XP002154312 *
FUJIKI H ET AL: "Japanese green tea as a cancer preventive in humans", NUTRITION REVIEWS,US,ALLEN PRESS, LAWRENCE, KS, vol. 54, no. 11, PART 02, November 1996 (1996-11-01), pages S67 - S70, XP002102790, ISSN: 0029-6643 *
HAQQI TARIQ M ET AL: "Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 8, 13 April 1999 (1999-04-13), April 13, 1999, pages 4524 - 4529, XP000961089, ISSN: 0027-8424 *
ISLAM SHABANA ET AL: "Inhibition of TNF-alpha-induced caspase-3 activity by epigallocatechin-3-gallate (EGCG) in human articular chondrocytes.", ARTHRITIS & RHEUMATISM, vol. 42, no. 9 SUPPL., 1999, 63rd Annual Scientific Meeting of the American College of Rheumatology and the 34th Annual Scientific Meeting of the Association of Rheumatology Health Professionals;Boston, Massachusetts, USA; Novemb, pages S92, XP000972239, ISSN: 0004-3591 *
KONO, KENJI ET AL: "Antibacterial activity of epigallocatechin gallate against Helicobacter pylori: synergistic effect with plaunotol", J. INFECT. CHEMOTHER. (1997), 3(3), 170-172, XP000957992 *
LIU S X L ET AL: "EFFECTS OF CHINESE HERBAL PRODUCTS ON MAMMALIAN RETINAL FUNCTIONS", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS,MARY ANN LIEBERT, INC., NEW YORK, NY,US, vol. 12, no. 3, 1996, pages 377 - 386, XP000957982, ISSN: 1080-7683 *
MCCARTY M F: "Polyphenol-mediated inhibition of AP-1 transactivating activity may slow cancer growth by impending angiogenesis and tumor invasiveness.", MEDICAL HYPOTHESES, vol. 50, no. 6, June 1998 (1998-06-01), pages 511 - 514, XP000957651, ISSN: 0306-9877 *
NAKACHI, KEI ET AL: "Epidemiological evidence for prevention of cancer and cardiovascular disease by drinking green tea", FOOD FACTORS CANCER PREV., [INT. CONF.] (1997), MEETING DATE 1995, 105-108. EDITOR(S): OHIGASHI, HAJIME. PUBLISHER: SPRINGER, TOKYO, JAPAN., XP000961375 *
PEARSON D A ET AL: "Inhibition of endothelial cell mediated low-density lipoprotein oxidation by green tea extracts", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 46, no. 4, April 1998 (1998-04-01), pages 1445 - 1449, XP002148223, ISSN: 0021-8561 *
TANIGUCHI S ET AL: "Effect of (-)- epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines", CANCER LETTERS,US,NEW YORK, NY, vol. 65, no. 1, 31 July 1992 (1992-07-31), pages 51 - 54, XP002102792, ISSN: 0304-3835 *
UEDA T ET AL: "PREVENTIVE EFFECT OF NATURAL AND SYNTHETIC ANTIOXIDANTS ON LIPID PEROXIDATION IN THE MAMMALIAN EYE", OPHTHALMIC RESEARCH,BASEL,CH, vol. 28, no. 3, 1996, pages 184 - 192, XP000957984 *
YAMADA, M. (1) ET AL: "Effects of tea polyphenols against Helicobacter pylori.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, (1997) VOL. 213, NO. 1-3, PP. AGFD 69. MEETING INFO.: 213TH NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY SAN FRANCISCO, CALIFORNIA, USA APRIL 13-17, 1997, XP000957983 *
ZIGMAN S ET AL: "TEA POLYPHENOL ANTIOXIDANTS RETARD LENS PHOTO-OXIDATION", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE,ASSOCIATION FOR RESEARCH IN VISION AND,US, vol. 39, no. 4, 15 March 1998 (1998-03-15), pages S317, XP000957974, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO2000047193A2 (en) 2000-08-17
SE9900473D0 (en) 1999-02-12
AU2567300A (en) 2000-08-29

Similar Documents

Publication Publication Date Title
WO2000047193A3 (en) Inhibition of angiogenesis with epigallocatechin-3-gallate
Gustafsson et al. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time
Carman et al. Treadmill injuries to the upper extremity in pediatric patients
Jeter et al. Skin care in the frail, elderly, dependent, incontinent patient
RU2003124748A (en) PHARMACEUTICAL COMPOSITIONS THAT SUPPRESS VASCULAR PROLIFERATION AND METHOD OF APPLICATION
WO2001057193A3 (en) Protein c derivatives
TR200200211T2 (en) Treatment and drug screening methods.
IS5177A (en) Use of 5- (4- (2- (N-methyl-N- (2-pyridyl) amino) -ethoxy) benzyl) 2,4-thiazolidinedione in the treatment of polycystic ovarian syndrome and gestational diabetes
Fleck et al. Newer debridement methods for wound bed preparation
Roehrborn Are all α-blockers created equal? An update
Cole et al. Adjuvant use of acoustic pressure wound therapy for treatment of chronic wounds: a retrospective analysis
Singh et al. Tangential excision and skin grafting for ash burns of the foot in children: a preliminary report
Gweon et al. Treatment of cyclophosphamide induced hemorrhagic cystitis with neodymium: YAG laser in pediatric patients
Keramidas et al. Adult hand injuries on artificial ski slopes
Rydén Managing cardiovascular risk in patients with diabetes
Vincenot et al. Physiology and cellular regulation of the protein C pathway
Rizzini et al. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients
Wadiwel et al. Joint Submission: Article 4 of the Optional Protocol to the Convention Against Torture
Lund-Johansen Intensive blood pressure treatment: beneficial for all but the smoking hypertensives?
Ortiz Meanwhile: Soon the Millennia, Burning Forests, Indians Killed, October 6, 1997
Lau et al. Two for one: salvage of bilateral lower extremities with a single free flap
Oakley A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge syndrome
ÖZDEMİR et al. NUTRITIONAL AND TOXIC OPTIC NEUROPATHIES
Kosova et al. The relentless Mrs. Dole.
Aglay China, India Lead Asia Race on GM Crops

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase